The treatment works, but the system doesn't know who to give it to.
Medicine finds itself in a rare and revealing bind: it has developed powerful new tools to treat obesity, yet it cannot agree on what obesity is. Across clinics, insurance offices, and research institutions, competing definitions — rooted in body mass index, metabolic markers, or disease frameworks — produce different diagnoses for the same patient. This definitional fracture is not merely academic; it shapes who receives care, who is denied it, and how a society understands one of its most prevalent health challenges. The treatments have arrived before the consensus, and the gap between them is measured in human consequence.
- Breakthrough medications like semaglutide are already in widespread use, yet the medical community cannot agree on the diagnostic criteria that would justify prescribing them.
- A single patient may be classified as obese by one physician and merely overweight by another, depending entirely on which definitional framework their doctor has adopted.
- Insurance companies, unable to anchor coverage decisions to a unified medical standard, create uneven and often arbitrary barriers to treatment access.
- Researchers and public health officials are hampered in tracking trends and designing interventions because the foundational category they are studying remains contested.
- Some medical organizations are pushing toward a chronic-disease model of obesity that incorporates genetics, hormones, and environment — but this emerging consensus has yet to crystallize into a shared diagnostic standard.
- The urgency is sharpening: with effective treatments now available, the absence of a clear definition no longer just complicates research — it actively delays care for patients who need it.
There is a paradox lodged at the center of modern obesity medicine: doctors have grown remarkably effective at treating a condition they cannot collectively define. GLP-1 receptor agonists like semaglutide and tirzepatide have demonstrated sustained weight loss and meaningful reductions in cardiovascular and metabolic risk. Cardiologists, endocrinologists, and primary care physicians are prescribing them with confidence. Yet the moment a physician attempts to formally document an obesity diagnosis — for a patient's chart, for an insurance claim, for a treatment protocol — the medical consensus dissolves.
The fault lines run deep. Some clinicians anchor their diagnosis in body mass index, the weight-to-height ratio that has long dominated clinical thinking. Others reject BMI as too blunt an instrument, arguing it ignores muscle mass, bone density, and fat distribution. Still others look to metabolic indicators — insulin resistance, inflammation, cardiovascular risk profiles — as the more honest measure of whether a patient's weight constitutes a genuine health threat. The result is a system in which the same person may receive different diagnoses depending on which office they walk into.
This fragmentation carries real costs. Insurance coverage for obesity treatments becomes inconsistent when the medical field itself cannot agree on diagnostic thresholds. Treatment protocols diverge between institutions. Epidemiologists cannot reliably compare data across populations. Public health strategies lose coherence when the condition they target lacks a shared definition.
The irony is that the therapeutic breakthroughs have made the definitional question more urgent, not less. If medicine cannot agree on who has obesity, it cannot agree on who should receive the drugs now capable of treating it. Some organizations are moving toward a chronic-disease model — one that incorporates hormonal dysregulation, genetic predisposition, and environmental factors — but this broader understanding has not yet produced a single accepted diagnostic framework.
In the meantime, patients absorb the cost of the confusion. Some go undiagnosed because their physician's definition does not match their insurer's. Others cycle through inconsistent advice from different specialists. The distance between what medicine can do and what it can agree to do is not an abstraction — it is the space in which vulnerable people wait.
The paradox sits at the heart of modern medicine: doctors have learned to treat obesity with increasing effectiveness, yet they cannot agree on what obesity actually is. New medications—GLP-1 receptor agonists chief among them—have shown remarkable results in helping patients lose weight and manage metabolic complications. Cardiologists, endocrinologists, and primary care physicians are prescribing these drugs with growing confidence. But the moment a doctor tries to formally diagnose obesity, to write it down in a patient's chart, to justify it to an insurance company, the consensus fractures.
The problem is deceptively simple: medicine lacks a unified definition of obesity. Some clinicians rely on body mass index, the ratio of weight to height that has dominated medical thinking for decades. Others argue BMI is crude and misleading, that it fails to account for muscle mass, bone density, or where on the body fat is actually stored. Still others point to metabolic markers—insulin resistance, inflammation, cardiovascular risk—as the true measure of whether someone's weight poses a genuine health threat. A patient might be classified as obese by one standard and merely overweight by another, depending on which doctor they see and which framework that doctor has adopted.
This definitional chaos creates real friction in the healthcare system. Insurance companies struggle to determine coverage for obesity treatments when the medical establishment itself cannot agree on diagnostic criteria. Treatment protocols vary wildly between hospitals and clinics. A patient deemed appropriate for medication in one setting might be denied it in another. The lack of standardized classification means that epidemiologists cannot reliably track obesity trends across populations, that researchers cannot easily compare treatment outcomes, and that public health officials cannot design coherent prevention strategies.
The irony deepens when you consider that the treatments themselves are working. Medications like semaglutide and tirzepatide have demonstrated the ability to produce sustained weight loss and reduce the risk of heart disease and diabetes. These are not marginal improvements—they represent a genuine therapeutic breakthrough. Yet this success in treatment has not prompted the medical community to resolve its definitional disputes. If anything, the existence of effective drugs has made the question more urgent: who exactly should receive them? Without agreement on what obesity is, how can doctors decide who has it?
Some medical organizations have begun moving toward consensus. There is growing recognition that obesity should be understood not merely as a weight problem but as a chronic disease with metabolic, genetic, and environmental components. This shift acknowledges that obesity is not simply a matter of willpower or lifestyle—that it involves dysregulation of appetite hormones, changes in how the body processes energy, and complex interactions between genes and environment. But even this broader understanding has not produced a single, universally accepted diagnostic framework.
The human cost of this confusion is substantial. Patients who might benefit from treatment are sometimes not diagnosed because their doctor uses a different definition than the one their insurance company recognizes. Others face delays in care while their medical team debates whether their condition meets the threshold for intervention. Still others are treated inconsistently, receiving different advice and different medications depending on which specialist they consult. The gap between what medicine can do and what it can agree to do leaves vulnerable people caught in the middle.
Moving forward, the medical community faces a choice. It can continue to operate with competing definitions, accepting the inefficiency and inequity that results. Or it can undertake the difficult work of building consensus—not by declaring one definition correct and dismissing the others, but by integrating what each framework has learned about how obesity actually works in human bodies. The treatments are ready. The question is whether the doctors who prescribe them can agree on what they are treating.
Notable Quotes
Some clinicians rely on body mass index, while others argue it fails to account for muscle mass, bone density, or fat distribution— Medical consensus on obesity classification
The Hearth Conversation Another angle on the story
Why does it matter how we define obesity if we can already treat it effectively?
Because definition determines access. Without agreement on what obesity is, insurance companies don't know when to cover treatment, and patients don't know if they qualify. The drug works, but the system doesn't know who to give it to.
So it's a bureaucratic problem, not a medical one?
It's both. The bureaucracy exists because medicine itself is divided. Some doctors see obesity as a weight problem, others as a metabolic disease, others as a cardiovascular risk factor. They're not wrong—they're just looking at different parts of the same thing.
Can't they just pick the best definition and move on?
That's the trap. There is no single best definition because obesity isn't one thing. It's a condition that shows up differently in different bodies. A unified definition has to account for that complexity without becoming so broad it's useless.
What happens to patients while doctors figure this out?
Some get treatment they need. Some don't. A patient might be denied medication by one insurance company but approved by another, depending on which diagnostic criteria that company recognizes. The treatment works, but access is random.
Is there movement toward consensus?
Yes, but slowly. There's growing agreement that obesity should be understood as a chronic disease involving metabolism and genetics, not just weight. But even that broader view hasn't produced a single diagnostic standard everyone accepts.